Colgate-Palmolive Beats Q2 Estimates, Raises EPS Growth Outlook
CL sits 20% above its 52-week low of $74.545.
Summary
Colgate-Palmolive delivered a Q2 beat with adjusted EPS of $0.99 versus the $0.95 consensus, while revenue rose 4.9% to $5.36 billion, matching expectations. Profit fell to $693 million from $743 million a year ago, but the company managed sales growth in all regions except North America, where sales dipped 3%. CEO Noel Wallace cited a difficult operating environment and expects volatility to persist, yet the company raised its full-year EPS growth guidance to mid-single-digit from low- to mid-single-digit, signaling confidence in navigating the choppy backdrop. This follows a 2025 marked by a $919 million impairment charge on the skin health business, making the current resilience notable. The guidance raise and broad-based international strength are the key takeaways for traders.
At the time of this announcement, CL was trading at $89.30 on NYSE in the Trade & Services sector, with a market capitalization of approximately $73.3B. The 52-week trading range was $74.55 to $99.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.